Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III pUDK-HGF for rest pain in critical limb ischemia
ChiCTR1800017462Phase 3Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Aug 2018
- Modality
- Gene Therapies, Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of pUDK-HGF in chronic limb-threatening ischemia (CLTI) and arteriosclerosis obliterans (2 arms), sponsored by Xuanwu Hospital. Primary endpoint: Day 180 pain completely healing rate. Started Aug 2018; status: recruiting.
02
Drugs
pUDK-HGF
03
Conditions
chronic limb-threatening ischemia (CLTI)arteriosclerosis obliterans
Beyond the preview
Go deeper on ChiCTR1800017462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017462.